NCT06618014View on ClinicalTrials.gov

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

January 10, 2025

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Toripalimab

Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.

DRUG

Docetaxel

Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.

DRUG

Carboplatin

Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06618014 - Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) | Biotech Hunter | Biotech Hunter